SillaJen Company Description

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea.

The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors.

It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial.

SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

SillaJen, Inc.

Country	South Korea
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	37
CEO	Jaekyung Kim

Contact Details

Address: 109, Sogong-ro Seoul South Korea
Phone	82 2 368 2600
Website	sillajen.com

Stock Details

Ticker Symbol	215600
Exchange	KOSDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	KRW
ISIN Number	KR7215600008
SIC Code	2836

Key Executives

Name	Position
Jaekyung Kim	Chief Executive Officer
Suk Song Myung	Chief Financial Officer